INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit
April 04, 2022 09:00 ET
|
INmune Bio, Inc.
INKmune™, unlike IL15 and other NK-activating cytokines, upregulates all mitochondrial survival proteins and more than 40 nutrient receptors on the NK cell to increase survival Boca Raton, Florida,...
INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit
March 30, 2022 08:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, March 30, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
March 25, 2022 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, March 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's Diseases
March 15, 2022 08:00 ET
|
INmune Bio, Inc.
Conference Provides First Exposure of EU and UK AD Experts to INmune Bio’s Approach of Targeting Neuroinflammation and Glial Activation with XPro™ for Treatment of Alzheimer’s Disease ...
INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference
March 14, 2022 16:30 ET
|
INmune Bio, Inc.
Boca Raton, FL, March 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system...
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update
March 03, 2022 16:00 ET
|
INmune Bio, Inc.
Cash of $74.8 million on December 31, 2021 Company to host conference call today, March 3, at 4:30pm ET Boca Raton, Florida, March 03, 2022 (GLOBE NEWSWIRE) -- INmune Bio,...
INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3
February 23, 2022 09:00 ET
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a...
INmune Bio, Inc. to Present at the BIO CEO & Investor Conference
February 08, 2022 09:00 ET
|
INmune Bio, Inc.
BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer
January 25, 2022 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Jan. 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting
January 04, 2022 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Jan. 04, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...